2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer
July 1, 2021
2cureX announces the presentation of the poster [P-288] “Individual Drug Screening and heterogeneity analysis of patient derived tumoroids – Roadmap to improving therapy in Pancreatic Cancer” at the 2021 ESMO World Congress on Gastrointestinal Cancer (ESMO GI) starting yesterday. The poster is presented jointly with the University Hospital of Hamburg – Eppendorf (UKE – Hamburg, Germany) as part of a collaboration to bring Functional Testing to Pancreatic Cancer.
The poster confirms the feasibility of using Functional Testing on resected tissue samples coming from the primary tumor, opening the door to an IndiTreat® application for those patients who receive adjuvant therapy after a surgical resection.
The collaboration of 2cureX with UKE in Pancreatic Cancer focuses on correlating Functional Testing results with clinical responses to adjuvant chemotherapy addressing the primary tumor. In parallel, 2cureX has another ongoing partnership in Pancreatic Cancer with the University Hospital Vejle (Vejle, Denmark), where the aim is to select treatments for patients with metastatic disease, that is, Stage IV.
“We are very excited about these results”, said Fernando Andreu, CEO of 2cureX. “Pancreatic Cancer is a very important area for 2cureX, and we have been working for a while on an IndiTreat® test for Stage IV Pancreatic Cancer. The results from our collaboration with the UKE mean we can eventually develop a second application for patients suffering from Pancreatic Cancer at earlier stages”.
The poster can be downloaded here.
Pancreatic Cancer is one of the most aggressive and lethal malignancies. More than 450,000 new cases of Pancreatic Cancer are diagnosed every year word wide. The 5-year survival rate is less than 10% and the therapeutic options are limited. The incidence of Pancreatic Cancer has increased over the past 10 years at a rate of approximately 1% per year. In the US, Pancreatic Cancer is expected to be the third leading cause of cancer related deaths in 2021, after Lung and Colorectal Cancer.
For more information about 2cureX:
Fernando Andreu, Chief Executive Officer
Telephone: +45 2279 5399
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient’s tumor and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient is given the selected treatment.
The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products will help patients at different stages of colorectal cancer and other solid cancers.
The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). For more information about 2cureX visit www.2cureX.com. Certified Adviser: Redeye AB, +46 8 121 576 90, firstname.lastname@example.org.